| Name | Title | Contact Details |
|---|---|---|
liakatali Bodalbhai |
Director R&D | Profile |
Liakat Bodalbhai |
Director R&D | Profile |
Virjinia Cortez |
Director, R&D Development Services | Profile |
Frank Sorgi |
VP of R&D | Profile |
Ecopia BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.
On Demand Pharmaceuticals (ODP) is developing the worlds most sophisticated distributed manufacturing platform.
3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.